|
Variable
|
Ptreat
|
Ptime
|
Zeolite
|
Placebo
|
Zeolite
|
Placebo
|
Reference range
|
|---|
|
0 week
|
0 week
|
12 weeks
|
12 weeks
|
|---|
|
zonulin
|
0.006
|
>0.1
|
61.2 ± 11.0
|
56.1 ± 13.2
|
43.8 ± 14.3
|
59.6 ± 12.3
|
<55
|
|
ng . mL-1
|
|
α1-antitrypsin
|
>0.1
|
>0.1
|
27.6 ± 14.8
|
32.8 ± 15.6
|
30.2 ± 18.1
|
35.8 ± 17.7
|
<37.5
|
|
mg . dL-1
|
|
CP
|
>0.1
|
<0.001
|
218 ± 102
|
206 ± 98
|
508 ± 108
|
486 ± 87
|
80–200
|
|
pmol . mg-1
|
|
iPF2α-III
|
>0.1
|
>0.1
|
216 ± 55
|
200 ± 55
|
199 ± 73
|
181 ± 43
|
50–400
|
|
pg . mL-1
|
|
GPx3
|
>0.1
|
<0.001
|
131 ± 69
|
107 ± 58
|
182 ± 64
|
193 ± 59
|
33–98
|
|
IU . L-1
|
|
DNA SB
|
>0.1
|
>0.1
|
0.36 ± 0.25
|
0.35 ± 0.24
|
0.49 ± 0.33
|
0.48 ± 0.29
|
0–70
|
|
AU
|
|
TNF-α
|
>0.1
|
0.024
|
26.1 ± 8.7
|
24.3 ± 12.3
|
31.8 ± 11.5
|
28.7 ± 11.8
|
0–69
|
|
pg . mL-1
|
|
IL-6
|
>0.1
|
>0.1
|
26.6 ± 2.0
|
27.1 ± 1.7
|
27.7 ± 3.2
|
26.9 ± 2.7
|
<100
|
|
pg . mL-1
|
|
IL-8
|
>0.1
|
>0.1
|
38.1 ± 10.8
|
41.9 ± 12.0
|
39.7 ± 11.5
|
39.8 ± 9.7
|
0–62
|
|
pg . mL-1
|
|
IL-10
|
0.087
|
>0.1
|
40.1 ± 19.2
|
42.1 ± 16.0
|
54.5 ± 27.8
|
37.9 ± 22.2
|
none
|
|
pg . mL-1
|
|
IL-22
|
>0.1
|
>0.1
|
42.9 ± 4.2
|
41.4 ± 3.3
|
40.5 ± 3.3
|
40.1 ± 4.4
|
none
|
|
pg . mL-1
|
- *Values are means ± SD; P < 0.05, ANOVA; n = 27 (Zeolite), n = 25 (Placebo); α1-antitrypsin alpha1-antitrypsin, CP carbonyl groups bounded on protein, iPF2α-III isoprostanes F2α-III, GPx3 plasma glutathione peroxidase, DNA SB DNA strand-breaks, TNF-α tumor necrose factor alpha, IL interleukin, treat treatment
